EPZM Epizyme Inc.

11.63
-0.11  -1%
Previous Close 11.74
Open 11.76
Price To Book 3.67
Market Cap 1,058,755,914
Shares 91,036,622
Volume 56,637
Short Ratio
Av. Daily Volume 650,702

NewsSee all news

  1. Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth

    Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointments of experienced commercial executive, Grant Bogle, and research and development

  2. Epizyme to Participate in Upcoming September Conferences

    Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in the following

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 dosing commenced August 2016. Noted April 23, 2018 that all Tazemetostat trials have been placed on partial clinical hold.
Tazemetostat
Adult patients with mesothelioma characterized by BAP1 loss-of-function
NDA filing due 4Q 2019.
Tazemetostat
Follicular lymphoma
PDUFA date priority review January 23, 2020.
Tazemetostat
Epithelioid Sarcoma
Phase 1b enrollment complete.
Tazemetostat + Atezolizumab
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Phase 1 trial to be initiated 2H 2019.
EZM8266
Sickle cell disease

Latest News

  1. Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth

    Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointments of experienced commercial executive, Grant Bogle, and research and development

  2. Epizyme to Participate in Upcoming September Conferences

    Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in the following